Pharmacologic shifting of a balance between protein refolding and degradation mediated by Hsp90
Christine Schneider(KLA (United States)), F. Ulrich Hartl(Max Planck Institute of Biochemistry), Laura Sepp‐Lorenzino(Intellia Therapeutics (United States)), Neal Rosen(Memorial Sloan Kettering Cancer Center), Samuel J. Danishefsky(Kettering University), Ouathek Ouerfelli(Memorial Sloan Kettering Cancer Center), Elmar Nimmesgern(Kettering University)
Cited by 409
Related Papers
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
|Cancer Research|2006|2.5k
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
|Nature|2010|1.8k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k
In vivo aspects of protein folding and quality control
|Science|2016|1.5k